115 related articles for article (PubMed ID: 4087135)
21. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
Ashforth EI; Carlile DJ; Chenery R; Houston JB
J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
[TBL] [Abstract][Full Text] [Related]
22. Simulation of differential drug pharmacokinetics under heat and exercise stress using a physiologically based pharmacokinetic modeling approach.
Sidhu P; Peng HT; Cheung B; Edginton A
Can J Physiol Pharmacol; 2011 May; 89(5):365-82. PubMed ID: 21627485
[TBL] [Abstract][Full Text] [Related]
23. A novel model for prediction of human drug clearance by allometric scaling.
Tang H; Mayersohn M
Drug Metab Dispos; 2005 Sep; 33(9):1297-303. PubMed ID: 15958605
[TBL] [Abstract][Full Text] [Related]
24. Modeled Rat Hepatic and Plasma Concentrations of Chemicals after Virtual Administrations Using Two Sets of in Silico Liver-to-Plasma Partition Coefficients.
Adachi K; Utsumi M; Sato T; Nakano H; Shimizu M; Yamazaki H
Biol Pharm Bull; 2023 Sep; 46(9):1316-1323. PubMed ID: 37380443
[TBL] [Abstract][Full Text] [Related]
25. Drug concentration in saliva.
Mucklow JC; Bending MR; Kahn GC; Dollery CT
Clin Pharmacol Ther; 1978 Nov; 24(5):563-70. PubMed ID: 29738
[TBL] [Abstract][Full Text] [Related]
26. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver.
Kanamitsu S; Ito K; Sugiyama Y
Pharm Res; 2000 Mar; 17(3):336-43. PubMed ID: 10801223
[TBL] [Abstract][Full Text] [Related]
27. Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver.
Sanoh S; Naritomi Y; Fujimoto M; Sato K; Kawamura A; Horiguchi A; Sugihara K; Kotake Y; Ohshita H; Tateno C; Horie T; Kitamura S; Ohta S
Xenobiotica; 2015; 45(7):605-14. PubMed ID: 25733030
[TBL] [Abstract][Full Text] [Related]
28. Prediction of drug distribution in vivo on the basis of in vitro binding data.
Schuhmann G; Fichtl B; Kurz H
Biopharm Drug Dispos; 1987; 8(1):73-86. PubMed ID: 3580515
[TBL] [Abstract][Full Text] [Related]
29. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man.
Tsuji A; Nishide K; Minami H; Nakashima E; Terasaki T; Yamana T
Drug Metab Dispos; 1985; 13(6):729-39. PubMed ID: 2867880
[TBL] [Abstract][Full Text] [Related]
30. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
Sayama H; Komura H; Kogayu M; Iwaki M
J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
[TBL] [Abstract][Full Text] [Related]
31. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
32. Exploration of PBPK Model-Calculation of Drug Time Course in Tissue Using IV Bolus Drug Plasma Concentration-Time Profile and the Physiological Parameters of the Organ.
Berezhkovskiy LM
J Pharm Sci; 2016 Aug; 105(8):2453-8. PubMed ID: 27290628
[TBL] [Abstract][Full Text] [Related]
33. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
[TBL] [Abstract][Full Text] [Related]
34. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals.
Matsushita H; Suzuki H; Sugiyama Y; Sawada Y; Iga T; Hanano M; Kawaguchi Y
J Pharmacobiodyn; 1990 Oct; 13(10):602-11. PubMed ID: 2095400
[TBL] [Abstract][Full Text] [Related]
35. Drug protein binding and the nephrotic syndrome.
Gugler R; Azarnoff DL
Clin Pharmacokinet; 1976; 1(1):25-35. PubMed ID: 797490
[TBL] [Abstract][Full Text] [Related]
36. QSAR analysis of blood-brain distribution: the influence of plasma and brain tissue binding.
Lanevskij K; Dapkunas J; Juska L; Japertas P; Didziapetris R
J Pharm Sci; 2011 Jun; 100(6):2147-60. PubMed ID: 21271563
[TBL] [Abstract][Full Text] [Related]
37. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
Berezhkovskiy LM
J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
[TBL] [Abstract][Full Text] [Related]
38. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.
Rane A; Wilkinson GR; Shand DG
J Pharmacol Exp Ther; 1977 Feb; 200(2):420-4. PubMed ID: 839445
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Tissue to Plasma Concentration Ratios of Drugs in the Rat from Experimentally Estimated Volume of Distribution: Application of Allometry.
Mahmood I
Curr Drug Metab; 2018; 19(2):155-164. PubMed ID: 29189141
[TBL] [Abstract][Full Text] [Related]
40. Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: emphasis on an apparent fraction unbound in liver for drugs.
Poulin P
J Pharm Sci; 2013 Jul; 102(7):2085-95. PubMed ID: 23613473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
